PDF(Pubmed)
Abstract：
UNASSIGNED: In Malaysia, following extensive COVID-19 vaccination, Hospital Kuala Lumpur reported an increase in cutaneous reactions post-immunisation. To understand this, a case-control study was initiated to identify potential risk factors.
UNASSIGNED: This registry-based, unmatched case-control study encompasses all adverse event following immunisation (AEFI) reports associated with COVID-19 vaccines, received by the Department of Pharmacy at Hospital Kuala Lumpur through the Malaysian Adverse Drug Reactions Advisory Committee (MADRAC) AEFI reporting forms. Twenty-four potential risk factors were evaluated, including demographic information, medical history, food allergies, COVID-19 vaccination history and prior SARS-CoV-2 infection, were evaluated using MADRAC AEFI reporting forms. Odds ratio (OR) with 95% confidence interval (CI) were estimated using univariable and multivariable logistic regression.
UNASSIGNED: Cutaneous reactions were more frequent in middle-aged females, especially after the first COVID-19 vaccine dose. These reactions, primarily mild and generalised, included pruritus and urticaria. Notably, 52% were delayed reactions (more than 4 h post-vaccination). Factors associated with increased risk of cutaneous reaction following COVID-19 immunisation included history of seafood and shellfish allergy (adjusted odds ratio [adjOR]: 2.11; 95% CI: 1.12, 3.96; P = 0.020), history of vaccine allergy (adjOR: 4.07; 95% CI: 1.44, 11.54; P = 0.008), past dermatological diseases (adjOR: 5.48; 95% CI: 2.03, 14.78; P = 0.001), and past medication allergy (adjOR: 2.12; 95% CI: 1.36, 3.31; P = 0.001).
UNASSIGNED: Self-reported histories of allergies to vaccines, foods or medications were found to increase the likelihood of cutaneous reactions following COVID-19 vaccination. These reactions, which were predominantly mild, did not hinder the administration of the second vaccine dose. The majority of reactions occurred after the first dose, manifesting as generalised pruritus and urticaria. They were effectively managed with oral antihistamines and low-dose corticosteroids, thereby avoiding the need for hospitalisation.
UNASSIGNED: This registry-based, unmatched case-control study encompasses all adverse event following immunisation (AEFI) reports associated with COVID-19 vaccines, received by the Department of Pharmacy at Hospital Kuala Lumpur through the Malaysian Adverse Drug Reactions Advisory Committee (MADRAC) AEFI reporting forms. Twenty-four potential risk factors were evaluated, including demographic information, medical history, food allergies, COVID-19 vaccination history and prior SARS-CoV-2 infection, were evaluated using MADRAC AEFI reporting forms. Odds ratio (OR) with 95% confidence interval (CI) were estimated using univariable and multivariable logistic regression.
UNASSIGNED: Cutaneous reactions were more frequent in middle-aged females, especially after the first COVID-19 vaccine dose. These reactions, primarily mild and generalised, included pruritus and urticaria. Notably, 52% were delayed reactions (more than 4 h post-vaccination). Factors associated with increased risk of cutaneous reaction following COVID-19 immunisation included history of seafood and shellfish allergy (adjusted odds ratio [adjOR]: 2.11; 95% CI: 1.12, 3.96; P = 0.020), history of vaccine allergy (adjOR: 4.07; 95% CI: 1.44, 11.54; P = 0.008), past dermatological diseases (adjOR: 5.48; 95% CI: 2.03, 14.78; P = 0.001), and past medication allergy (adjOR: 2.12; 95% CI: 1.36, 3.31; P = 0.001).
UNASSIGNED: Self-reported histories of allergies to vaccines, foods or medications were found to increase the likelihood of cutaneous reactions following COVID-19 vaccination. These reactions, which were predominantly mild, did not hinder the administration of the second vaccine dose. The majority of reactions occurred after the first dose, manifesting as generalised pruritus and urticaria. They were effectively managed with oral antihistamines and low-dose corticosteroids, thereby avoiding the need for hospitalisation.
摘要：
■在马来西亚，在广泛接种COVID-19疫苗后，吉隆坡医院报告免疫接种后皮肤反应增加。为了理解这一点，我们启动了一项病例对照研究,以确定潜在的危险因素.
■此基于注册表的，无与伦比的病例对照研究涵盖了与COVID-19疫苗相关的免疫接种（AEFI）报告后的所有不良事件，吉隆坡医院药剂科通过马来西亚药品不良反应咨询委员会(MADRAC)AEFI报告表格收到。评估了24个潜在的危险因素，包括人口统计信息，病史,食物过敏,COVID-19疫苗接种史和SARS-CoV-2感染史，使用MADRACAEFI报告表进行评估。使用单变量和多变量逻辑回归估计具有95％置信区间（CI）的比值比（OR）。
■皮肤反应在中年女性中更为常见，特别是在第一剂COVID-19疫苗接种后。这些反应,主要是温和和普遍的，包括瘙痒和荨麻疹。值得注意的是,52％为延迟反应（疫苗接种后4小时以上）。与COVID-19免疫接种后皮肤反应风险增加相关的因素包括海鲜和贝类过敏史(调整比值比[adjOR]:2.11;95%CI:1.12,3.96;P=0.020)，疫苗过敏史(adjOR:4.07;95%CI:1.44,11.54;P=0.008),过去的皮肤病（调整：5.48;95％CI：2.03，14.78;P=0.001），和既往药物过敏(adjOR:2.12;95%CI:1.36,3.31;P=0.001)。
■自我报告的疫苗过敏史，发现食物或药物会增加COVID-19疫苗接种后皮肤反应的可能性。这些反应,主要是温和的，不妨碍第二次疫苗剂量的给药。大多数反应发生在第一次给药后，表现为广泛性瘙痒和荨麻疹。他们有效地管理与口服抗组胺药和低剂量的皮质类固醇，从而避免了住院治疗的需要。
■此基于注册表的，无与伦比的病例对照研究涵盖了与COVID-19疫苗相关的免疫接种（AEFI）报告后的所有不良事件，吉隆坡医院药剂科通过马来西亚药品不良反应咨询委员会(MADRAC)AEFI报告表格收到。评估了24个潜在的危险因素，包括人口统计信息，病史,食物过敏,COVID-19疫苗接种史和SARS-CoV-2感染史，使用MADRACAEFI报告表进行评估。使用单变量和多变量逻辑回归估计具有95％置信区间（CI）的比值比（OR）。
■皮肤反应在中年女性中更为常见，特别是在第一剂COVID-19疫苗接种后。这些反应,主要是温和和普遍的，包括瘙痒和荨麻疹。值得注意的是,52％为延迟反应（疫苗接种后4小时以上）。与COVID-19免疫接种后皮肤反应风险增加相关的因素包括海鲜和贝类过敏史(调整比值比[adjOR]:2.11;95%CI:1.12,3.96;P=0.020)，疫苗过敏史(adjOR:4.07;95%CI:1.44,11.54;P=0.008),过去的皮肤病（调整：5.48;95％CI：2.03，14.78;P=0.001），和既往药物过敏(adjOR:2.12;95%CI:1.36,3.31;P=0.001)。
■自我报告的疫苗过敏史，发现食物或药物会增加COVID-19疫苗接种后皮肤反应的可能性。这些反应,主要是温和的，不妨碍第二次疫苗剂量的给药。大多数反应发生在第一次给药后，表现为广泛性瘙痒和荨麻疹。他们有效地管理与口服抗组胺药和低剂量的皮质类固醇，从而避免了住院治疗的需要。
